Health and Healthcare
AbbVie Soars on Solid Earnings and Guidance
Published:
Last Updated:
AbbVie Inc. (NYSE: ABBV) reported its third-quarter financial results before the markets opened on Friday. The company had $1.13 in earnings per share (EPS) on $5.94 billion in revenue. Thomson Reuters consensus estimates had called for $1.08 in EPS on revenue of $5.89 billion. In the same period of the previous year, it posted EPS of $0.89 and $5.02 billion in revenue.
Sales growth in the third quarter was driven by the continued strength of Humira and other promoted products. Global Humira sales increased 19.6% on an operational basis, or 12.1% including the impact of foreign exchange rate fluctuations.
At the same time, Imbruvica sales were $304 million, with U.S. sales of $267 million and international profit sharing of $37 million for the quarter. Viekira sales also drove total company sales growth with $469 million in global sales.
Gross margin in the third quarter was 83.3%, with a gross margin expansion of 220 basis points that was driven by product mix, operating efficiencies and the impact of foreign exchange rates.
In terms of guidance, AbbVie raised its EPS expectations for the full year to $4.26 to $4.28, compared to the consensus estimate of $4.24.
Richard A. Gonzalez, chairman and CEO of AbbVie, commented on earnings:
We are pleased with our outperformance in the third quarter and our progress year-to-date. We’ve driven strong commercial, operational and R&D execution, resulting in industry-leading top- and bottom-line performance. We are well-positioned to deliver robust EPS growth in 2015 and beyond, and we continue to make significant progress advancing our pipeline and other strategic actions that will help AbbVie achieve top-tier growth over the long term.
Shares of AbbVie closed Thursday up 1.6% at $54.10, with a consensus analyst price target of $74.07 and a 52-week trading range of $45.45 to $71.60. Following the release of the earnings report, shares were up nearly 5% at $56.74 in early trading indications on Friday.
ALSO READ: The 10 Most Profitable Companies in the World
Travel Cards Are Getting Too Good To Ignore
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.